Haleon Plc ADR (HLN)
NYSE
Closed
Oct 7, 2026
Day's Range
9.0152 wk Range
8.65Overview - HLN - Haleon Plc ADR
Key Statistics
Valuation
Enterprise Value
64.39B
P/E (Trailing)
‪19.29‬
P/E (Forward)
‪14.98‬
PEG Ratio
‪14.98‬
Price / Sales (TTM)
‪3.65‬
Price / Book
‪1.87‬
EV / EBITDA
‪17.07‬
Profitability
Gross Margin
‪55.38%‬
Profit Margin
‪14.55%‬
Operating Margin
‪23.93%‬
Return on Assets
‪5.08%‬
Return on Equity
‪10.09%‬
Ownership
Shares Outstanding
8.90B
Float
4.42B
Short % of Shares Outstanding
‪0.50%‬
Held by Insiders
‪0.01%‬
Held by Institutions
‪13.65%‬
Price stats
Beta
‪0.24‬
50-Day Avg
‪9.75‬
200-Day Avg
‪9.82‬
Dividends
Payout Ratio
‪39.53%‬
Frequency
Semi-Annual
Analyst Consensus
5 analysts
Average price target
‪$ 11.99‬Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - HLN - Haleon Plc ADR
Peers - HLN - Haleon Plc ADR
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NYSE.
Profile Summary - HLN - Haleon Plc ADR
About
Haleon Plc - ADR represents an American Depositary Receipt for Haleon Plc, a company known for its focus on consumer healthcare products. ADRs are traded on U.S. stock exchanges and allow American investors to invest in non-U.S. companies without dealing with foreign transactions. Haleon Plc specializes in providing…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
